Acceptability of HPV vaccination among young adults aged 18-30 years-a population based survey in Sweden

Vaccine

Volumn 28, Issue 47, 2010, Pages 7492-7500

  Sundström, Karin ^a   Tran, Trung Nam ^a   Lundholm, Cecilia ^a   Young, Cecilia ^b   Sparén, Pär ^a   Dahlström, Lisen Arnheim ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Sanofi Pasteur MSD   (Sweden)

Author keywords

Acceptability; Adults; HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CONDYLOMA ACUMINATUM; CROSS-SECTIONAL STUDY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH BEHAVIOR; HUMAN; MALE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SWEDEN; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH BEHAVIOR; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; SEXUALLY TRANSMITTED DISEASES, VIRAL; SWEDEN; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 77958179926     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.007     Document Type: Article

References (43)

1. Ferlay J.B.F., Pisani P., Parkin D.M. GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC CancerBase No. 5 version 2.0 2004, IARC Press, Lyon.
2. IARC. IARC Monographs on the evaluation of carcinogenic risks to humans, volume 90, human papillomaviruses. Lyon, France: International Agency on Cancer Research; 2007.
3. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009 Jul, 374(9686):301-314.
4. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007 Jun, 369(9576):1861-1868.
5. Schiller J.T., Castellsague X., Villa L.L., Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008 Aug, 26(Suppl 10):K53-K61.
6. Wright T.C., Bosch F.X., Franco E.L., Cuzick J., Schiller J.T., Garnett G.P., et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 2006 Aug, 24(Suppl 3). S3/251-61.
7. Giuliano A.R. Human papillomavirus vaccination in males. Gynecol Oncol 2007 Nov, 107(2 Suppl 1):S24-S26.
8. Giuliano A.R., Tortolero-Luna G., Ferrer E., Burchell A.N., de Sanjose S., Kjaer S.K., et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008 Aug, 26(Suppl 10):K17-K28.
9. Parkin D.M., Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006 Aug, 24(Suppl 3). S3/11-25.
10. Palefsky J.M. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010 Apr, 46(4 Suppl):S12-S19.
11. Nasman A., Attner P., Hammarstedt L., Du J., Eriksson M., Giraud G., et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?. Int J Cancer 2009 Jul, 125(2):362-366.
12. Petaja T., Keranen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009 Jan, 44(1):33-40.
13. CDC. Gardasil Update: Safety and Efficacy in Boys and Men ACIP. 2009 [cited 2009-09-20]; Available from: http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun09/06-2-hpv.pdf.
14. SVEVAC. Excerpt from the Swedish Vaccination Register (SVEVAC). May 2010.
15. Socialstyrelsen. [Regulations from the National Board of Health and Welfare concerning changes in regulations (SOSFS 2006:22) concerning vaccination of children. SOSFS 2008:31]. 2008.
16. Waller J., McCaffery K., Wardle J. Beliefs about the risk factors for cervical cancer in a British population sample. Prev Med 2004 Jun, 38(6):745-753.
17. de Visser R., McDonnell E. Correlates of parents' reports of acceptability of human papilloma virus vaccination for their school-aged children. Sex Health 2008 Dec, 5(4):331-338.
18. Kulasingam S.L., Pagliusi S., Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine 2007 Nov, 25(48):8110-8113.
19. Zimet G.D., Shew M.L., Kahn J.A. Appropriate use of cervical cancer vaccine. Annu Rev Med 2008, 59:223-236.
20. Brewer N.T., Fazekas K.I. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007 Aug-Sep, 45(2-3):107-114.
21. Black L.L., Zimet G.D., Short M.B., Sturm L., Rosenthal S.L. Literature review of human papillomavirus vaccine acceptability among women over 26 years. Vaccine 2009 Mar, 27(11):1668-1673.
22. Dahlstrom L.A., Tran T.N., Lundholm C., Young C., Sundstrom K., Sparen P. Attitudes to HPV vaccination among parents of children aged 12-15 years-A population-based survey in Sweden. Int J Cancer 2009 Jun.
23. Ferris D.G., Waller J.L., Miller J., Patel P., Jackson L., Price G.A., et al. Men's attitudes toward receiving the human papillomavirus vaccine. J Low Genit Tract Dis 2008 Oct, 12(4):276-281.
24. Marshall H., Ryan P., Roberton D., Baghurst P. A cross-sectional survey to assess community attitudes to introduction of Human papillomavirus vaccine. Aust N Z J Public Health 2007 Jun, 31(3):235-242.
25. Sauvageau C., Duval B., Gilca V., Lavoie F., Ouakki M. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 2007, 7:304.
26. Walsh C.D., Gera A., Shah M., Sharma A., Powell J.E., Wilson S. Public knowledge and attitudes towards Human Papilloma Virus (HPV) vaccination. BMC Public Health 2008, 8:368.
27. Liddon N., Hood J., Wynn B.A., Markowitz L.E. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 2010 Feb, 46(2):113-123.
28. Reiter P.L., Brewer N.T., McRee A.L., Gilbert P., Smith J.S. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis 2010 Mar, 37(3):197-203.
29. Reiter P.L., Brewer N.T., Smith J.S. Human papillomavirus knowledge and vaccine acceptability among a national sample of heterosexual men. Sex Transm Infect 2010 May.
30. Gerend M.A., Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis 2009 Jan, 36(1):58-62.
31. Kjaer S.K., Tran T.N., Sparen P., Tryggvadottir L., Munk C., Dasbach E., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007 Nov, 196(10):1447-1454.
32. Särndal C., Swensson B., Wretman J. Model Assisted Survey Sampling 1992, Springer-Verlag, New York.
33. Munoz N., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on All HPV-associated genital diseases in young women. J Natl Cancer Inst 2010 Mar, 102(5):325-339.
34. Donders G.G., Gabrovska M., Bellen G., Van Keirsbilck J., Van Den Bosch T., Riphagen I., et al. Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium. Arch Gynecol Obstet 2008 Apr, 277(4):291-298.
35. Hoglund A.T., Tyden T., Hannerfors A.K., Larsson M. Knowledge of human papillomavirus and attitudes to vaccination among Swedish high school students. Int J STD AIDS 2009 Feb, 20(2):102-107.
36. Marlow L.A., Forster A.S., Wardle J., Waller J. Mothers' and adolescents' beliefs about risk compensation following HPV vaccination. J Adolesc Health 2009 May, 44(5):446-451.
37. Kahn J.A., Rosenthal S.L., Jin Y., Huang B., Namakydoust A., Zimet G.D. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol 2008 May, 111(5):1103-1110.
38. Di Giuseppe G., Abbate R., Liguori G., Albano L., Angelillo I.F. Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. Br J Cancer 2008 Jul, 99(2):225-229.
39. Kwan T.T., Chan K.K., Yip A.M., Tam K.F., Cheung A.N., Lo S.S., et al. Acceptability of human papillomavirus vaccination among Chinese women: concerns and implications. BJOG 2009 Mar, 116(4):501-510.
40. Jones M., Cook R. Intent to receive an HPV vaccine among university men and women and implications for vaccine administration. J Am Coll Health 2008 Jul-Aug, 57(1):23-32.
41. Keating K.M., Brewer N.T., Gottlieb S.L., Liddon N., Ludema C., Smith J.S. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health 2008 Oct, 43(4 Suppl):S61-S67.
42. Donders G.G., Bellen G., Declerq A., Berger J., Van Den Bosch T., Riphagen I., et al. Change in knowledge of women about cervix cancer, human papilloma virus (HPV) and HPV vaccination due to introduction of HPV vaccines. Eur J Obstet Gynecol Reprod Biol 2009 Apr.
43. Mortensen G.L. Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study. BMC Public Health 2010, 10:68.